Datapoint: FDA Grants Tentative Nod to Xyrem Rival

The FDA last week granted tentative approval to Avadel Pharmaceuticals’ narcolepsy drug Lumryz, a potential rival to Jazz Pharmaceuticals’ Xyrem, pending the resolution of a patent dispute between the two companies. Lumryz’s main advantage over Xyrem is its extended-release formula, whereas Xyrem requires two nightly doses. For the treatment of narcolepsy, Xyrem currently holds covered or better status for 96% of all insured lives in the U.S. under the pharmacy benefit. About 20% of insured lives have preferred access to Xyrem, largely with utilization management restrictions applied.

Source: MMIT Analytics, as of 7/27/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: New Startup Insurer to Expand to Six More States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: FDA Approves Lilly’s Interchangeable Insulin

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today